| Literature DB >> 33673740 |
János Németh1, Beáta Tapasztó1,2, Wagih A Aclimandos3, Philippe Kestelyn4, Jost B Jonas5, Jan-Tjeerd H N De Faber6, Ingrida Januleviciene7, Andrzej Grzybowski8,9, Zoltán Zsolt Nagy1, Olavi Pärssinen10, Jeremy A Guggenheim11, Peter M Allen12, Rigmor C Baraas13, Kathryn J Saunders14, Daniel Ian Flitcroft15,16, Lyle S Gray17, Jan Roelof Polling18,19, Annechien Eg Haarman18, J Willem L Tideman18, James Stuart Wolffsohn20, Siegfried Wahl21,22, Jeroen A Mulder19, Irina Yurievna Smirnova23, Marino Formenti24, Hema Radhakrishnan25, Serge Resnikoff26,27.
Abstract
The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, the European Society of Ophthalmology decided to publish this update of the current information and guidance on management of myopia. The pathogenesis and genetics of myopia are also summarized and epidemiology, risk factors, preventive and treatment options are discussed in details.Entities:
Keywords: Myopia; atropine; blindness; myopia reduction interventions; orthokeratology; pathologic myopia; preventive medicine; time spent outdoors
Year: 2021 PMID： 33673740 DOI： 10.1177/1120672121998960
Source DB: PubMed Journal: Eur J Ophthalmol ISSN： 1120-6721 Impact factor: 2.597